Literature DB >> 29559727

Kappa counterconditioning of cocaine cues.

John R Mantsch1, Robert C Twining2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29559727      PMCID： PMC5983536          DOI： 10.1038/s41386-018-0037-5

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  10 in total

1.  U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking.

Authors:  S Schenk; B Partridge; T S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  1999-06       Impact factor: 4.530

2.  Drug addiction: II. an aversive counterconditioning technique for treatment.

Authors:  C D Copemann
Journal:  Psychol Rep       Date:  1976-06

3.  A comparison of therapies for the treatment of drug cues: counterconditioning vs. extinction in male rats.

Authors:  Brendan J Tunstall; Andrey Verendeev; David N Kearns
Journal:  Exp Clin Psychopharmacol       Date:  2012-12       Impact factor: 3.157

4.  Dopamine neurons report an error in the temporal prediction of reward during learning.

Authors:  J R Hollerman; W Schultz
Journal:  Nat Neurosci       Date:  1998-08       Impact factor: 24.884

5.  Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria.

Authors:  Michael R Bruchas; Benjamin B Land; Megumi Aita; Mei Xu; Sabiha K Barot; Shuang Li; Charles Chavkin
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

6.  The Aversive Agent Lithium Chloride Suppresses Phasic Dopamine Release Through Central GLP-1 Receptors.

Authors:  Samantha M Fortin; Elena H Chartoff; Mitchell F Roitman
Journal:  Neuropsychopharmacology       Date:  2015-07-27       Impact factor: 7.853

7.  Distinct Subpopulations of Nucleus Accumbens Dynorphin Neurons Drive Aversion and Reward.

Authors:  Ream Al-Hasani; Jordan G McCall; Gunchul Shin; Adrian M Gomez; Gavin P Schmitz; Julio M Bernardi; Chang-O Pyo; Sung Il Park; Catherine M Marcinkiewcz; Nicole A Crowley; Michael J Krashes; Bradford B Lowell; Thomas L Kash; John A Rogers; Michael R Bruchas
Journal:  Neuron       Date:  2015-09-02       Impact factor: 17.173

8.  Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion.

Authors:  Vladimir I Chefer; Cristina M Bäckman; Eduardo D Gigante; Toni S Shippenberg
Journal:  Neuropsychopharmacology       Date:  2013-07-18       Impact factor: 7.853

9.  The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward.

Authors:  Hilarie C Tomasiewicz; Mark S Todtenkopf; Elena H Chartoff; Bruce M Cohen; William A Carlezon
Journal:  Biol Psychiatry       Date:  2008-07-17       Impact factor: 13.382

10.  Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons.

Authors:  Jonathan M Ehrich; Daniel I Messinger; Cerise R Knakal; Jamie R Kuhar; Selena S Schattauer; Michael R Bruchas; Larry S Zweifel; Brigitte L Kieffer; Paul E M Phillips; Charles Chavkin
Journal:  J Neurosci       Date:  2015-09-16       Impact factor: 6.167
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.